CytoGenX Corp. Announces the Release of Assure™ Whole-Genome Microarray
ACOG and ACMG issue new guidelines supporting the utilization of cytogenomic microarray analysis as appropriate diagnostic testing for prenatal, postnatal, infertility and oncology samples.
Stony Brook, NY (PRWEB) December 12, 2013
CytoGenX Corp, a leading provider of medical genetic testing services, announced today it will be offering Assure™, its new comprehensive whole-genome microarray designed to aid in the detection and identification of disease-causing genetic alterations involved in prenatal and pediatric genetic diseases as well as cancer and infertility. "Assure™, is an unprecedented diagnostic-tool capable of analyzing every gene in the human genome and will serve to advance the diagnosis and treatment of countless known and unknown human diseases," said Joseph A. Gebbia, Ph.D., founder and CEO of CytoGenX Corp.
December, 2013- The American College of Obstetrics and Gynecologists (ACOG) issued new guidelines for the utilization of chromosomal microarray (CMA) in prenatal diagnostic testing. According to these guidelines CMA should be offered to all patients undergoing an amniocentesis or CVS and should not be restricted to women age 35 and older.
The American College of Medical Genetics (ACMG) issued revised guidelines supporting the utilization of cytogenomic microarray analysis as “first-tier” diagnostic testing for both postnatal and prenatal samples (September, 2013) and for complementing the diagnosis of neoplastic disorders (April, 2013).
The Assure™ platform, offered by CytoGenX Corp.,will have a profound effect on the ability to provide state of the art genetic technology to patients. Assure™ SNP array can detect complex genomic changes not apparent by either karyotype or FISH and has applications for prenatal, postnatal and oncology. CMA technology provides higher resolution than karyotyping and therefore allows genome wide screening for microdeletions and microduplications. Submicroscopic rearrangements account for as much as 15% of human genetic disease.
Assure™ whole-genome SNP microarray, provided by CytoGenX, targets the entire genome utilizing 2.67 million markers for copy number analysis, 750,000 SNP markers and 1.9 million non-polymorphic probes. The platform offers excellent performance and exceeds current guidelines for specificity and resolution across the entire genome. The high probe density provides comprehensive coverage with 100% Sanger cancer gene coverage, 100% ICCG (formerly ISCA) constitutional gene coverage, 12,000 OMIN and 36,000 RefSeq genes on a single array. The presence of single-nucleotide polymorphism (SNP) markers enables high-solution copy number analysis to detect gains and losses in DNA, loss of heterozygosity (LOH), regions identical-by-descent, uniparental disomy (UPD) and mosaicism.
CytoGenX provides the most innovative genetic technology available for the diagnosis of complex pregnancy, infertility, cancer and genetic disease. As an international provider of advanced medical genetic services, CytoGenX is committed to providing a multidisciplinary approach in the management of genetic disease. The focus of our highly specialized team of professionals is to empower clinicians and patients with an understanding of genetic disease and risk that allows for the most informed decision-making possible. CytoGenX strives to increase the quality and longevity of human life through genetic testing. Since our inception, CytoGenX has continuously offered the most recent advances in clinically relevant technologies in medical genetics.
For the original version on PRWeb visit: http://www.prweb.com/releases/cytogenx/assure-microarray/prweb11416344.htm